Information for Human Cells, Tissues, or Cellular or Tissue-based Products Establishments

For Public Health

At a glance

CDC works with the U.S. Food and Drug Administration (FDA); state, territorial, and local health departments; and Human Cells, Tissues, or Cellular or Tissue-based Products (HCT/P) establishments to help ensure the safety of the HCT/P supply.

Female doctor working on her notebook computer in her office.

What to know

On May 20, 2024, the FDA withdrew the “Guidance for Industry, Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products (Updated May 2018).” Please access the following website for further information regarding withdrawal: Information for Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) Establishments Regarding FDA's Determination that Zika Virus is no Longer a Relevant Communicable Disease Agent or Disease | FDA.

To access archived HCT/P donor screening information used prior to the date of withdrawal, please access these websites:

Content Source
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
About This Page
Published: May 15, 2024
Updated: May 21, 2024

This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.

Reviewed: October 26, 2026

The information on this page was last reviewed by subject matter experts to ensure accuracy.